Anthrax Vaccine Adsorbed, Adjuvanted (CYFENDUS)
Anthrax Vaccine Adsorbed, Adjuvanted is an FDA-licensed reference biologic from Emergent Product Development Gaithersburg, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2023
Reference approved
Reference product
CYFENDUS Anthrax Vaccine Adsorbed, Adjuvanted
Emergent Product Development Gaithersburg, Inc.
- Approved
- Jul 20, 2023
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Anthrax Vaccine Adsorbed, Adjuvanted, in chronological order.
Reference approval
Approval date of the reference Anthrax Vaccine Adsorbed, Adjuvanted product.
2 yr 11 mo ago
Frequently asked questions
Are there biosimilars approved for Anthrax Vaccine Adsorbed, Adjuvanted (CYFENDUS)?
No 351(k) biosimilars or interchangeable biosimilars referencing Anthrax Vaccine Adsorbed, Adjuvanted are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.